Publications by authors named "T J Triche"
Acute Myeloid Leukemia (AML) is an aggressive cancer with dismal outcomes, vast subtype heterogeneity, and suboptimal risk stratification. In this study, we harmonized DNA methylation data from 3,314 patients across 11 cohorts to develop the Acute Leukemia Methylome Atlas (ALMA) of diagnostic relevance that predicted 27 WHO 2022 acute leukemia subtypes with an overall accuracy of 96.3% in discovery and 90.
View Article and Find Full Text PDFAlmost 50% of patients with myelodysplastic syndrome (MDS) are refractory to first-line hypomethylating agents (HMAs), which presents a significant clinical challenge considering the lack of options for salvage. Past work revealed that immune checkpoint molecules on peripheral myeloblasts and immune cells are up-regulated after HMA treatment. Therefore, we conducted a Phase I/II clinical trial combining guadecitabine (an HMA) and atezolizumab (an immune checkpoint inhibitor) to treat HMA-relapsed or refractory (HMA-R/R) MDS patients.
View Article and Find Full Text PDFArticle Synopsis
- In men with metastatic hormone-sensitive prostate cancer (mHSPC), new treatments help many live longer, but how well each person does can be really different.
- Researchers are looking at a blood test that counts tiny cancer cells (CTCs) to see if it can help predict a patient’s survival.
- They studied 503 men to see if the number of CTCs in their blood was linked to how long they lived and how well their treatment worked.
Article Synopsis
- Alternative lengthening of telomeres (ALT) is found in sarcomas, and this study investigates its frequency in Ewing's family sarcoma (EFS), rhabdomyosarcoma (RMS), and osteosarcoma (OS) using a specific PCR assay to detect telomeric DNA C-circles.
- After analyzing DNA from 273 primary tumor samples, results showed ALT in 0% of EFS, 2.7% of RMS, and 71% of OS, indicating a significant variability in ALT presence among these cancers.
- The findings suggest that the C-circle assay (CCA) is an effective method for identifying ALT in sarcomas and could serve as a valuable tool